ARVINAS, INC. Q3 FY2024 earnings call

John Houston discussed the company's pipeline, including the advanced program Vepdeg, an orally bioavailable PROTAC protein degrader for ER+/HER2- breast cancer. He also mentioned ARV-102 for neurodegenerative diseases, ARV-393 for non-Hodgkin lymphoma, and the upcoming investigational new drug application for the KRAS G-12B program. Noah Berkowitz provided an update on the VERITAC-2 trial, expecting top line data by end of 2024 or Q1 2025, and discussed combination trials with other therapies. Andrew Sake shared financial highlights, noting $1.1 billion in cash, cash equivalents, and marketable securities at the end of Q3 2024.

During the third quarter ended September 30, 2024, Arvinas recorded $102.4 million in revenue, compared to $34.6 million in the same period of 2023. General and administrative expenses were $75.8 million in Q3 2024, up from $22.6 million in Q3 2023. Research and development expenses were $86.9 million in Q3 2024, slightly up from $85.9 million in Q3 2023.

Arvinas expects to share top line data from the Phase 3 VERITAC-2 trial by the end of 2024 or first quarter of 2025. The company is planning for potential Phase 3 combination trials in 2025, evaluating data from various studies to inform these trials.

Risks include uncertainties related to clinical trial outcomes, regulatory approvals for new drugs, and market acceptance of new treatments. There are also risks associated with the competitive landscape and the ability to successfully develop and commercialize new product candidates.

Q: Should investors base their case on Pfizer moving with CDK4 inhibitor combo with Vepdeg in first and second line?

A: John Houston noted excitement about upcoming data and the potential of CDK4 + Vepdeg combination, with data from ongoing combinations to drive decisions.

Q: How to frame expectations for the fulvestrant control arm in VERITAC-2?

A: Noah Berkowitz stated expectation of fulvestrant arm PFS in 3-4 month range, with Vepdeg arm expecting a few months better.

Q: Talk about the size of PD population for ARV-102 and biomarker use?

A: Angela Cacace mentioned estimated 30% of idiopathic Parkinson's disease population with elevated LRRK2, and partnering to understand biomarker-based patient segmentation.

Q: What are key regulatory inputs for Phase 3 combo trials?

A: Noah Berkowitz discussed need for health authority discussions, with considerations on comparator arms and data from ongoing studies to inform final trial design.